Top of the morning to you and a fine one, it is. Blue skies and crisp breezes are enveloping the serene Pharmalot campus this morning, where the short person remains hunched over a laptop and the official mascot is sprinting about the grounds in search of creatures. This means we are happily focused on the important matters at hand — brewing cups of stimulation (blueberry is our choice today) and foraging for items of interest. On that note, here are a few. May today be productive, satisfying, and safe. Meanwhile, do keep in touch. …
The Covid-19 vaccine developed by the University of Oxford and AstraZeneca (AZN) produces a strong immune response in healthy adults 56 to 69 years old and people over 70, The Telegraph telegraphs. Phase 2 data, published in The Lancet, suggests one of the groups most vulnerable to serious illness and death from Covid-19 could build immunity. There were also fewer serious side effects than in younger volunteers. Phase 3 trials of the vaccine are ongoing, with early efficacy readings possible in the coming weeks.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
